Adagene (ADAG) vs ADC Therapeutics SA (ADCT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Adagene (ADAG) has outperformed ADC Therapeutics SA (ADCT) over the past year, gaining 41.2% versus a loss of 67.1%. Over five years, ADAG leads with a -76.0% price change compared with -94.4% for ADCT. Adagene is the larger company by market cap ($188.7 million vs $181.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADAG | ADCT |
|---|---|---|
| Share price | $2.81 | $1.42 |
| Market cap | $188.67M | $181.29M |
| 1-day change | -4.10% | +11.81% |
| YTD return | +48.68% | -59.77% |
| 1-year return | +41.21% | -67.05% |
| 5-year return | -75.98% | -94.42% |
| EPS (TTM) | $-0.37 | $-0.60 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.85 | $4.98 |
| 52-week low | $1.30 | $0.78 |
| Distance from 52-week high | -42.06% | -71.49% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +252.67% | +134.51% |
| Average volume | 246.37K | 1.34M |
| Shares outstanding | 67.14M | 127.67M |
| Employees | 128 | 188 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ADAG has outperformed ADCT by 108.3 percentage points over the past year.
About Adagene
ADAG stock →Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 128 employees
About ADC Therapeutics SA
ADCT stock →ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.
Health Care · Biotechnology: Pharmaceutical Preparations · 188 employees
ADAG vs ADCT FAQ
Which is bigger, Adagene or ADC Therapeutics SA?
Adagene (ADAG) is larger, with a market capitalization of $188.67M compared with $181.29M for ADC Therapeutics SA (ADCT).
Which stock has performed better over the past year, ADAG or ADCT?
ADAG returned +41.21% over the past 12 months, compared with -67.05% for ADCT (price return, excluding dividends). Past performance does not predict future results.
Are Adagene and ADC Therapeutics SA in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.